|
Energex Systems, Inc. is dedicated to the development, manufacturing
and marketing of patented therapeutic medical devices that use energy sources
innovatively to treat chronic conditions and diseases. Founded in 1999, the
company has developed two very unique, patented medical technologies, both
having international appeal to patients and the medical community alike because
of the conditions they treat.
Energex® Device:
The Company's first innovative product, Energex Device, is now
available and on the market for the relief of chronic TMJ pain. Using pulsed
radio frequency energy, Energex Device is a safe, effective, non-invasive
therapy administered in minutes to patients. Clinical research performed at
Tufts University School of Dental Medicine was the basis for Energex'
successful application to the Food and Drug Administration for approval to
market the device for the treatment of chronic TMJ pain.
Based on initial research, the company anticipates that Energex
Device will prove effective for a wide range of inflammatory conditions,
including osteoarthritis and carpal tunnel syndrome. Additional studies are
underway at Tufts University to clinically establish the efficacy of the
therapy in the treatment of joint pain of the knee.
Hemo-Modulator technology:
Ultra-violet light in the C band (UVC) energy treatment of
blood-borne diseases such as Hepatitis C, HIV/AIDS and other Ribonucleic Acid
(RNA) viruses. Unlike conventional drug therapies that are limited by the
patient's ethnicity and geno-types we are hopeful that our clinical studies
will establish that this unique therapy is safe and highly effective in all
ethnic groups and genotypes.
Preliminary results of our Hepatitis C clinical trial performed at
Warren Hospital in Phillipsburg, NJ, have shown substainial reductions in viral
load for most of the trial participants treated with the Hemo-Modulator
technology. The trial is being conducted under an Investigational Device
Exemption (IDE) that was granted by the Federal Food and Drug Administration
(FDA) in October 2004. In the trial, the average viral load reduction of the
first three participants was approximately 81% in just a 17-day period, and
there have been no adverse events.
|
